Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.42
PFE's Cash-to-Debt is ranked lower than
74% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. PFE: 0.42 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3  Med: 0.9 Max: 3.47
Current: 0.42
0.3
3.47
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
83% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.46 Max: 0.62
Current: 0.35
0.35
0.62
Interest Coverage 11.58
PFE's Interest Coverage is ranked lower than
70% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. PFE: 11.58 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 10.39 Max: 18.94
Current: 11.58
5.27
18.94
Piotroski F-Score: 6
Altman Z-Score: 2.22
Beneish M-Score: -2.55
WACC vs ROIC
8.77%
14.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 25.99
PFE's Operating Margin % is ranked higher than
90% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.38 vs. PFE: 25.99 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 14.53  Med: 23.82 Max: 29.44
Current: 25.99
14.53
29.44
Net Margin % 13.66
PFE's Net Margin % is ranked higher than
76% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. PFE: 13.66 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 16.8 Max: 42.65
Current: 13.66
12.67
42.65
ROE % 11.51
PFE's ROE % is ranked higher than
64% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.12 vs. PFE: 11.51 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 27.93
Current: 11.51
9.29
27.93
ROA % 4.24
PFE's ROA % is ranked higher than
53% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. PFE: 4.24 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.3
Current: 4.24
4.05
12.3
ROC (Joel Greenblatt) % 58.36
PFE's ROC (Joel Greenblatt) % is ranked higher than
86% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.08 vs. PFE: 58.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 82.01
Current: 58.36
40.74
82.01
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
53% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 3.8 Max: 18.1
Current: 4.7
-2.5
18.1
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 4.3 Max: 35.6
Current: -10.1
-10.1
35.6
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
73% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: -0.8 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 4 Warning Signs with Pfizer Inc $PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PFE Guru Trades in Q1 2016

David Dreman 5,820 sh (New)
Joel Greenblatt 1,577,263 sh (New)
Paul Singer 3,925,482 sh (New)
John Burbank 3,171,356 sh (+1860.75%)
John Paulson 1,378,100 sh (+117.81%)
Jana Partners 13,460,304 sh (+46.81%)
Keeley Asset Management Corp 104,500 sh (+34.41%)
Pioneer Investments 10,669,986 sh (+30.44%)
NWQ Managers 2,518,601 sh (+28.00%)
Mairs and Power 4,402,543 sh (+12.96%)
Ray Dalio 460,039 sh (+5.90%)
Diamond Hill Capital 11,245,591 sh (+4.89%)
David Tepper 2,512,250 sh (+4.15%)
First Eagle Investment 141,061 sh (+3.98%)
Murray Stahl 68,472 sh (+3.84%)
John Buckingham 78,483 sh (+2.08%)
T Rowe Price Equity Income Fund 14,730,900 sh (+1.42%)
Richard Pzena 2,187,104 sh (+1.18%)
RS Investment Management 1,644,965 sh (+0.66%)
Ronald Muhlenkamp 38,409 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
John Paulson 800,000 sh (unchged)
David Carlson 300,000 sh (unchged)
Leon Cooperman Sold Out
Alan Fournier Sold Out
Barrow, Hanley, Mewhinney & Strauss 53,724,766 sh (-0.26%)
Jeff Auxier 85,899 sh (-0.38%)
Manning & Napier Advisors, Inc 726,260 sh (-1.19%)
Ken Fisher 31,746,148 sh (-1.82%)
Charles Brandes 5,536,325 sh (-1.83%)
Jeremy Grantham 5,800,868 sh (-2.96%)
Kahn Brothers 1,442,543 sh (-8.11%)
Ruane Cunniff 12,442 sh (-16.22%)
Vanguard Health Care Fund 7,267,526 sh (-18.09%)
Mario Gabelli 537,011 sh (-24.04%)
Lee Ainslie 8,232,303 sh (-27.14%)
Paul Tudor Jones 14,600 sh (-58.17%)
Dodge & Cox 929,604 sh (-58.56%)
Jim Simons 2,416,341 sh (-69.74%)
Andreas Halvorsen 1,117,592 sh (-84.95%)
» More
Q2 2016

PFE Guru Trades in Q2 2016

Tom Russo 19,900 sh (New)
David Dreman 29,962 sh (+414.81%)
Lee Ainslie 18,426,824 sh (+123.84%)
Jeremy Grantham 12,281,814 sh (+111.72%)
Paul Tudor Jones 21,500 sh (+47.26%)
Pioneer Investments 15,488,287 sh (+45.16%)
Joel Greenblatt 1,938,282 sh (+22.89%)
Ray Dalio 560,639 sh (+21.87%)
Diamond Hill Capital 11,646,559 sh (+3.57%)
Mairs and Power 4,482,288 sh (+1.81%)
Jeff Auxier 85,899 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
David Carlson 300,000 sh (unchged)
Vanguard Health Care Fund Sold Out
David Tepper Sold Out
Jana Partners Sold Out
Andreas Halvorsen Sold Out
Paul Singer Sold Out
Richard Pzena 2,186,404 sh (-0.03%)
Ken Fisher 31,724,530 sh (-0.07%)
Murray Stahl 68,255 sh (-0.32%)
Ronald Muhlenkamp 37,049 sh (-3.54%)
Mario Gabelli 517,941 sh (-3.55%)
John Buckingham 75,656 sh (-3.60%)
Keeley Asset Management Corp 100,600 sh (-3.73%)
T Rowe Price Equity Income Fund 13,941,800 sh (-5.36%)
Charles Brandes 5,231,096 sh (-5.51%)
Barrow, Hanley, Mewhinney & Strauss 48,981,192 sh (-8.83%)
Manning & Napier Advisors, Inc 651,040 sh (-10.36%)
Dodge & Cox 830,581 sh (-10.65%)
NWQ Managers 2,095,468 sh (-16.80%)
Kahn Brothers 1,156,866 sh (-19.80%)
Jim Simons 1,745,400 sh (-27.77%)
First Eagle Investment 76,061 sh (-46.08%)
RS Investment Management 793,005 sh (-51.79%)
Ruane Cunniff 5,930 sh (-52.34%)
John Paulson 510,400 sh (-62.96%)
John Burbank 420,192 sh (-86.75%)
» More
Q3 2016

PFE Guru Trades in Q3 2016

Jim Simons 8,566,241 sh (+390.79%)
Lee Ainslie 21,380,155 sh (+16.03%)
NWQ Managers 2,360,862 sh (+12.67%)
Ray Dalio 626,339 sh (+11.72%)
Richard Pzena 2,329,636 sh (+6.55%)
Diamond Hill Capital 11,856,263 sh (+1.80%)
Mairs and Power 4,555,073 sh (+1.62%)
Ken Fisher 31,836,368 sh (+0.35%)
David Carlson 300,000 sh (unchged)
David Dreman 29,962 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Eric Mindich 3,050,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Ruane Cunniff Sold Out
Tom Russo Sold Out
T Rowe Price Equity Income Fund 13,875,000 sh (-0.48%)
Manning & Napier Advisors, Inc 645,026 sh (-0.92%)
Jeff Auxier 85,015 sh (-1.03%)
John Burbank 409,366 sh (-2.58%)
Ronald Muhlenkamp 36,034 sh (-2.74%)
Mario Gabelli 502,386 sh (-3.00%)
Murray Stahl 65,882 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 47,267,043 sh (-3.50%)
Charles Brandes 5,032,007 sh (-3.81%)
John Buckingham 72,763 sh (-3.82%)
Dodge & Cox 773,142 sh (-6.92%)
Keeley Asset Management Corp 91,630 sh (-8.92%)
Pioneer Investments 13,857,332 sh (-10.53%)
First Eagle Investment 66,061 sh (-13.15%)
Paul Tudor Jones 17,200 sh (-20.00%)
Kahn Brothers 919,757 sh (-20.50%)
Joel Greenblatt 1,158,937 sh (-40.21%)
Jeremy Grantham 6,716,818 sh (-45.31%)
John Paulson 252,000 sh (-50.63%)
» More
Q4 2016

PFE Guru Trades in Q4 2016

Steven Cohen 214,100 sh (New)
David Tepper 4,810,000 sh (New)
Eaton Vance Worldwide Health Sciences Fund 1,462,345 sh (New)
John Paulson 352,200 sh (+39.76%)
Diamond Hill Capital 12,957,027 sh (+9.28%)
Lee Ainslie 22,851,570 sh (+6.88%)
Manning & Napier Advisors, Inc 684,000 sh (+6.04%)
Murray Stahl 69,400 sh (+5.34%)
Charles Brandes 5,271,418 sh (+4.76%)
Mairs and Power 4,725,178 sh (+3.73%)
John Buckingham 74,141 sh (+1.89%)
Ken Fisher 32,204,753 sh (+1.16%)
T Rowe Price Equity Income Fund 13,900,000 sh (+0.18%)
David Carlson 300,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
John Burbank Sold Out
Mario Gabelli 490,448 sh (-2.38%)
Keeley Asset Management Corp 89,323 sh (-2.52%)
Dodge & Cox 748,972 sh (-3.13%)
NWQ Managers 2,280,229 sh (-3.42%)
Barrow, Hanley, Mewhinney & Strauss 45,401,940 sh (-3.95%)
Richard Pzena 2,217,509 sh (-4.81%)
Ronald Muhlenkamp 33,984 sh (-5.69%)
Kahn Brothers 860,290 sh (-6.47%)
Jeremy Grantham 5,451,421 sh (-18.84%)
Pioneer Investments 9,476,885 sh (-31.61%)
Joel Greenblatt 759,374 sh (-34.48%)
Paul Tudor Jones 10,900 sh (-36.63%)
David Dreman 18,901 sh (-36.92%)
Ray Dalio 282,200 sh (-54.94%)
Jim Simons 2,847,000 sh (-66.76%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:MRK, NYSE:NVS, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:BMY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.

Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study The study compared Xeljanz to Humira
The top-line results from the Oral Strategy trial of Xeljanz were announced Feb. 16 by Pfizer Inc. (NYSE:PFE) through the Business Wire. Read more...
David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Procter & Gamble, Pfizer Lead Market Gains 3 indexes reach new highs on Wednesday
U.S. market indexes continued to gain on Wednesday with all three leading indexes reaching new highs. Read more...
Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Biosimilar for rheumatoid arthritis treatment demonstrated equivalent efficacy
Pfizer Inc. (NYSE:PFE) announced through the Business Wire on Jan. 5 that the results from a phase 3 study assessing the efficiency of PF-06410293, a biosimilar of AbbVie’s (NYSE:ABBV) Humira, in treating patients affected by rheumatoid arthritis met its primary endpoint. Read more...
Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Which Criteria Best Determine the Success of Mergers? An evaluation of 3 recent mergers
Throughout the past three months, several mergers, including the $14 billion merger between Pfizer Inc. (NYSE:PFE) and Medivation Inc. (NASDAQ:MDVN), were announced. In part one of our study, we discussed how the John Paulson Merger Arb Checklist determines the success rate of mergers. This article will further the study by analyzing some of the recent mergers and predicting the success rate based on historical results. Read more...
Pfizer Acquires Medivation Company will pay $14 billion for biopharmaceutical business
Pfizer (NYSE:PFE) reported Monday that it would be acquiring, biopharmaceutical company, Medivation (NASDAQ:MDVN). Pfizer will pay $81.50 per share for a total value of approximately $14 billion. Shares of Medivation opened higher on Monday and gained approximately 20%. Read more...
Is Pfizer on Its Way Up? Patent expirations are countered by Hospira gains and organic growth
Pfizer (NYSE:PFE) finally had a good run this past six months. After what seemed to be an unstoppable slide in top line revenues, the company finally showed an impressive 15% increase to $26.2 billion from $22.7 billion in the year-ago six-month period. Unfortunately, the bottom line didn’t see much of that increase, and only went to $5.02 billion from $5 billion last year -- about 1% growth. Read more...
Pfizer Beats 2nd Quarter Revenue and Earnings Estimates Health care reporting good second-quarter results
Pfizer (NYSE:PFE) recently reported its second-quarter earnings with a revenue and earnings per share beat for the quarter. Pfizer is the final health care company in the Dow Jones Industrial Average to report earnings for the quarter. In the health care industry all four companies in the Dow Jones Industrial Average have beat revenue and earnings per share estimates for the quarter. Read more...
Gabelli Funds Comments on Pfizer Inc. Guru stock highlight
Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016. Read more...

Ratios

vs
industry
vs
history
PE Ratio 29.29
PFE's PE Ratio is ranked lower than
54% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.06 vs. PFE: 29.29 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 16.1 Max: 34.77
Current: 29.29
7.68
34.77
Forward PE Ratio 13.39
PFE's Forward PE Ratio is ranked higher than
64% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.82 vs. PFE: 13.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.04
PFE's PE Ratio without NRI is ranked lower than
54% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.19 vs. PFE: 29.04 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 19.14 Max: 34.43
Current: 29.04
9.83
34.43
Price-to-Owner-Earnings 18.98
PFE's Price-to-Owner-Earnings is ranked higher than
72% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.27 vs. PFE: 18.98 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.92 Max: 36.49
Current: 18.98
5.44
36.49
PB Ratio 3.50
PFE's PB Ratio is ranked lower than
60% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. PFE: 3.50 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.42 Max: 3.57
Current: 3.5
1.32
3.57
PS Ratio 4.00
PFE's PS Ratio is ranked lower than
64% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. PFE: 4.00 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.64 Max: 4.75
Current: 4
1.72
4.75
Price-to-Free-Cash-Flow 15.18
PFE's Price-to-Free-Cash-Flow is ranked higher than
66% of the 185 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.92 vs. PFE: 15.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.06 Max: 17.52
Current: 15.18
5.02
17.52
Price-to-Operating-Cash-Flow 13.26
PFE's Price-to-Operating-Cash-Flow is ranked higher than
62% of the 233 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.34 vs. PFE: 13.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 11.75 Max: 15.46
Current: 13.26
4.55
15.46
EV-to-EBIT 23.97
PFE's EV-to-EBIT is ranked lower than
61% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.61 vs. PFE: 23.97 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.45 Max: 28.8
Current: 23.97
6.7
28.8
EV-to-EBITDA 14.95
PFE's EV-to-EBITDA is ranked higher than
55% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.32 vs. PFE: 14.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 14.95
4.9
17.3
Shiller PE Ratio 21.92
PFE's Shiller PE Ratio is ranked higher than
80% of the 157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.81 vs. PFE: 21.92 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.12  Med: 16.35 Max: 21.98
Current: 21.92
9.12
21.98
Current Ratio 1.25
PFE's Current Ratio is ranked lower than
77% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. PFE: 1.25 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 1.54 Max: 2.58
Current: 1.25
1.25
2.58
Quick Ratio 1.03
PFE's Quick Ratio is ranked lower than
73% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. PFE: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.28 Max: 2.31
Current: 1.03
1.03
2.31
Days Inventory 219.07
PFE's Days Inventory is ranked lower than
86% of the 567 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.74 vs. PFE: 219.07 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.24 Max: 344.63
Current: 219.07
185.33
344.63
Days Sales Outstanding 56.83
PFE's Days Sales Outstanding is ranked higher than
70% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. PFE: 56.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 69.5 Max: 106.89
Current: 56.83
56.83
106.89
Days Payable 134.30
PFE's Days Payable is ranked higher than
82% of the 471 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. PFE: 134.30 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 115.45 Max: 179.46
Current: 134.3
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.55
PFE's Dividend Yield % is ranked higher than
86% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. PFE: 3.55 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.67 Max: 10.4
Current: 3.55
2.9
10.4
Dividend Payout Ratio 1.03
PFE's Dividend Payout Ratio is ranked lower than
72% of the 378 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. PFE: 1.03 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 1.03
0.58
1.08
3-Year Dividend Growth Rate 7.70
PFE's 3-Year Dividend Growth Rate is ranked lower than
51% of the 270 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.7 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.74
PFE's Forward Dividend Yield % is ranked higher than
87% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 3.74 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.31
PFE's 5-Year Yield-on-Cost % is ranked higher than
92% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. PFE: 5.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.49 Max: 15.57
Current: 5.31
4.34
15.57
3-Year Average Share Buyback Ratio 1.80
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. PFE: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: -4 Max: 7.2
Current: 1.8
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.09
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.61 vs. PFE: 1.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.04 Max: 6.59
Current: 1.09
0.62
6.59
Price-to-Median-PS-Value 1.10
PFE's Price-to-Median-PS-Value is ranked higher than
58% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.22 vs. PFE: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.13 Max: 2.72
Current: 1.1
0.6
2.72
Earnings Yield (Greenblatt) % 4.19
PFE's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 611 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. PFE: 4.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.9
Current: 4.19
3.5
14.9
Forward Rate of Return (Yacktman) % 3.33
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
61% of the 353 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.48 vs. PFE: 3.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.3  Med: 12.5 Max: 22.8
Current: 3.33
3.3
22.8

More Statistics

Revenue (TTM) (Mil) $52,825
EPS (TTM) $ 1.17
Beta1.02
Short Percentage of Float0.55%
52-Week Range $28.74 - 37.39
Shares Outstanding (Mil)5,951.87

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 53,473 53,733 53,007
EPS ($) 2.58 2.79 2.74
EPS without NRI ($) 2.58 2.79 2.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.10%
Dividends per Share ($) 1.27 1.79 1.48
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Pfizer Reports Top-Line Results For Rheumatoid Arthritis Treatment Study Feb 27 2017 
Dow Jones Leads Market Gains on Thursday Feb 23 2017 
Why 3D Printing and Biotech Will Be Good Bets in 2017 Feb 23 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Procter & Gamble, Pfizer Lead Market Gains Feb 16 2017 
ANGEL Program Gets National Attention Feb 13 2017 
US Market Indexes Regain Some of Their Losses on Wednesday Feb 02 2017 
A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017 

More From Other Websites
Drugmakers pledge restraint, but prices will still soar Feb 27 2017
Drugmakers pledge restraint, but prices will still soar Feb 27 2017
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study Feb 27 2017
Why You Shouldn't Look Down On Your Depressed Colleagues Feb 27 2017
Pfizer’s Products with Falling Revenues in 4Q16 Feb 27 2017
[$$] VC Profile: OrbiMed Funds Novel Attacks on Cancer Feb 27 2017
Understanding Pfizer’s Growth Contributors in 4Q16 Feb 27 2017
Pfizer’s Innovative Health and Essential Health in 4Q16 Feb 27 2017
Merck & Co.’s Valuation after Its 4Q16 Earnings Feb 27 2017
Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer Feb 27 2017
5:59 am Pfizer announces pricing of $1,065,000,000 aggregate principal amount of 4.20% notes due... Feb 27 2017
Details Still Missing on Republicans' 'Once in a Generation' Tax Plan Feb 25 2017
Pfizer subpoenaed in U.S. over patient assistance plans Feb 24 2017
Pfizer subpoenaed in U.S. over patient assistance plans Feb 24 2017
Pfizer subpoenaed in U.S. over patient assistance plans Feb 24 2017
Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections Feb 24 2017
Pfizer’s Valuation after Its 4Q16 Earnings Release Feb 24 2017
Pfizer Prices $1,065,000,000 Debt Offering Feb 24 2017
Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; stable outlook Feb 24 2017
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs Feb 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)